seizing the mkt opportunity/ current mkt conditions in the usa is a good example

Hi folks/

Can i share this with you all

A Goldman Sachs article in January '21

" The Biden administration said it has reached a $230 million deal with Australian diagnostics company Ellume USA LLC to produce at-home, over-the-counter Covid-19 tests.The Food and Drug Administration previously authorized the test. So far, the FDA has cleared three Covid-19 tests that can be processed entirely at home, but Ellume’s is the only one that doesn’t require a prescription. None are widely available at this point.The company is expected to produce 19 million tests a month by the end of the year, Andy Slavitt, senior adviser to the White House Covid-19 response team, said Monday. Based on the agreement, 8.5 million tests will be guaranteed to the U.S. government."


19 m tests per month is 228m tests per year if the production target and demand for ellume is hit to start by 4th quarter of the usa markets ie Oct -Dec 21

If we negotiate a royalty of $1usd per test that's revenue of potentially $228m $usd for ADO a year

Goldman Sachs just last week wrote another piece on rapid antigen tests citing a fall in demand for inferior rat tests and quoted the ceo of Ellume saying that demand was exceedingly high for their highly accurate rapid antigen test

This translates into a vital point of differentiation for ADO / Ellume in manufacturing world class rat tests that are and will continue to be in high demand around the world.

I would like to see ADO re-pricing a FORWARD looking Ellume contract on usd/dollars per unit sold rather than a standard volume price.

The move to commercialization and monetization of our technology and product takes patience and requires traction.

We have the momentum now given the delta variant is crushing the western/ and asian world as they head into autumn and winter and im sure we will see results in coming weeks

Patience is required here / but i do see the positive comments from the Ellume ceo as affirming the state of play and demand in the market for a world class rapid antigen test like ours

keeping the faith

ohh and share prices fluctuate and get revalued on outcomes and momentum
there's no question we have the momentum and the strategy is rolling out / and lets not forget that doing international business in a covid world of lock downs, minimal international travel and a largely immobile world gripped in a headlock of viral contagion.
Lets adjust our expectations to account for some delays.


keeping the faith in the good